Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06892691 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions

Study acronym: PERFECT-MPE
StatusCompleted
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Final enrollment: 75 participants (planned 98)
    • Primary and study completion dates changed from estimate of Sep 17, 2026 to Aug 30, 2026
    • Start date: Mar 24, 2025 to Mar 19, 2025
    • Eligibility criteria expanded, about 11 words
    • Site details revised at 2 of 2 sites
  2. Start date changed from estimate of Mar 2025 to Mar 24, 2025
    • Site contacts updated at 2 of 2 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.
Trial Details
NCT Number NCT06892691
Lead Sponsor Icahn School of Medicine at Mount Sinai
Conditions
(from sponsor)		 Pleural Effusion, Cancer
Related terms Neoplasms, Pleural Effusion
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov